CLINICAL IMPACT OF THE FUNGICIDAL ACTIVITY OF CASPOFUNGIN ADMINISTERED ALONE OR IN COMBINATION IN CRITICALLY ILL PATIENTS WITH SEVERE ABDOMINAL CANDIDIASIS REFRACTORY TO CONVENTIONAL ANTIFUNGAL DRUGS: CASE STUDIES AND CRITICAL REVIEW OF THE PROBLEM

REFERENCES

• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of ca-spofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347: 2020–9
   PubMed Web of Science ®Google Scholar
• Sandven P, Qvist H, Skovlund E, et al. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med. 2002; 30: 541–6
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002; 40: 1298–302
   PubMed Web of Science ®Google Scholar
• Rocco TR, Reinert SE, Simms HR. Effects of fluconazole admi-nistration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg. 2000; 135: 160–5
   PubMed Web of Science ®Google Scholar
• Dupont H, Paugam-Burtz C, Muller-Serieys C, et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg. 2002; 137: 1341–6
   PubMed Web of Science ®Google Scholar
• Guideline. Management of deep Candida infection in surgical and intensive care unit patient. British Society for Antimicrobial Chemotherapy Working Party. Intensive Care Med. 1994; 20: 522–8
   PubMed Web of Science ®Google Scholar
• Petri MG, Konig J, Moecke HP, et al. Epidemiology of invasive mycosis in ICU patients: a prospect multicenter study in 435 non-neutropenic patients. Paul-Ehrl Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med. 1997; 23: 317–25
   PubMed Web of Science ®Google Scholar
• Rotstein OD, Pruett TL, Simmons RL. Microbiologic features and treatment of persistent peritonitis patients in the intensive care unit. Can J Surg. 1986; 29: 247–50
   PubMed Web of Science ®Google Scholar
• Ibrahim EH, Sherman G, Ward S, et al. The influence of in-adequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000; 118: 9–11
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002; 15: 982–9
   Google Scholar
• Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Re-sults of a prospective study on patients with Candida fungemia. J Infect Dis. 1998; 177: 425–30
   PubMed Web of Science ®Google Scholar
• Huang YC, Kao HT, Lin TY, et al. Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia. Am J Perinatol. 2001; 18: 141–6
   PubMed Web of Science ®Google Scholar
• Haynes K. Virulence in Candida species. Trends Microbiol. 2001; 9: 591–6
   PubMed Web of Science ®Google Scholar
• Shafran PP, Rotstein GG, Smaill F, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candi-demia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997; 16: 337–45.
   PubMed Web of Science ®Google Scholar
• Sorkine P, Nagar H, Weinbroum A, et al. Administration of am-photericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med. 1996; 24: 1311–5
   PubMed Web of Science ®Google Scholar
• Pacetti SA, Gelone SP. Caspofungin acetate for treatment of invasive fungal infection. Ann Pharmacother 2003; 37: 90–8
   PubMed Web of Science ®Google Scholar
• Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000; 44: 368–77
   PubMed Web of Science ®Google Scholar
• de Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000; 26: 915–21
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001; 32: 686–93
   PubMed Web of Science ®Google Scholar
• Graybill JR.. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract. 2001; 55: 633–8
   Google Scholar
• Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002; 40: 2228–30
   PubMed Web of Science ®Google Scholar
• Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspo-fungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31: 183–7.
   PubMed Web of Science ®Google Scholar
• Lewis RE, Lund BC, Klepser ME, et al. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother 1998; 42: 1382–6
   PubMed Web of Science ®Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evalutation studies with the echinocandin antifungal MK-0991 (L-73,872). Antimicrob Agents Chemother 1997; 41: 2326–32
   PubMed Web of Science ®Google Scholar
• Roling EE, Klepser ME, Wasson A, et al. Antifungal activities of fluconazole, caspofungin (MK0991) and anidulafungin (LY 303366) alone and in combination against Candida spp. And Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis. 2002; 43: 13–7
   PubMed Web of Science ®Google Scholar
• Hossain MA, Reyes GH, Long LA, et al. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 2003; 51: 1427–9
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025–32
   PubMed Web of Science ®Google Scholar
• Voitl P, Scheibenpflug C, Weber T, et al. Combined antifungal treatment of visceral mucormycosis with caspofungin and lipo-somal amphotericin B. Eur J Clin Microbiol Infect Dis. 2002; 21: 632–4
   PubMed Web of Science ®Google Scholar
• Lum LR, Turco TF, Leone J. Combination therapy with caspofun-gin and amphotericin B lipid complex. Am J Health Syst Phann. 2002; 59: 80–1
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs. 2001; 10: 1545–58
   PubMed Web of Science ®Google Scholar
• Ripeau JS, Aumont F, Belhumeur P, et al. Effect of the echino-candin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother. 2002; 46: 3096–100
   PubMed Web of Science ®Google Scholar
• Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echi-nocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44: 2310–8
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Can-dida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 1108–11
   PubMed Web of Science ®Google Scholar
• Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol infect. 2001; 7: 11–6
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary asper-gillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857–69
   PubMed Web of Science ®Google Scholar